The Galien Forum USA 2019

October 24th 2019
Alexandria Center – New York City

 The Galien Forum, held every autumn at Alexandria Center for Life Science – New York, offers a full day of spirited discussions with Nobel Laureates, top policymakers, and leading industry executives who offer perspectives on the most significant health challenges of our time while highlighting the latest research and clinical pathways toward diagnosis, treatment, and cure.

PANEL 1

Digital Health Transformation – Orchestrating patient-centricity from molecule to market

07:45 am – 08:50 am

Panel Introduction    Register

Chair
MaryAnne Rizk,
SVP Digital R&D Strategy
IQVIA

Panelists
Emmanuel Fombu,
Global Strategy and Digital Innovation Leader
Johnson & Johnson

Karl Hick,
Chief Digital and Information Officer
Takeda Pharmaceuticals, Inc.

Jon Resinick,
President, Real World Evidence
IQVIA

Jim Scholefield,
Chief Information and Digital Officer
Merck & Co., Inc.

Panelist bios

PANEL 2

Can Disruptive Innovation Positively Impact Healthcare Costs?

08:55 am – 10:00 am

Panel Introduction    Register

Co-Chairs
Joel S. Marcus
Executive Chairman & Founder
Alexandria Real
Estate Equities, Inc./
Alexandria Venture Investments
Co-Founder
Alexandria Summit

Lynne Zydowsky, PhD
Chief Science Officer
Alexandria Real
Estate Equities, Inc./
Alexandria Venture Investments
President and Co-Founder
Alexandria Summit

PANEL 3

Drugging the Undruggable with Novel Approaches to Small Molecule Design

10:15 am – 11:20 am

In the journey of drug discovery and development, scientists are continually uncovering new
pathways for treatment, often with a focus on either dialing up or dialing back the activity of a
specific molecular target. Historically, this has involved identifying a protein that has a
“druggable” binding pocket that can be targeted with a small molecule, or to design antibodies
that bind to a specific known antigen.

Panel Introduction   Register

Moderator
Mikael Dolsten, MD, PhD
Chief Scientific Officer and President, Worldwide Research, Development and Medical (WRDM)
Pfizer

Panelists
Karin Briner, VP
Head Global Discovery Chemistry
Novartis Institutes for BioMedical Research, Cambridge, MA

Alessio Ciulli
Professor of Chemical and Structural Biology School of Life Sciences, University of Dundee Division of Biological Chemistry & Drug Discovery,
Dundee, UK

Craig Crews
Founder and CSO of Arvinas
US Market Access
New Haven, CT

Jennifer Petter
CSO of Arrakis
Waltham, MA

Michael Ringel
Senior Partner & Managing Director at Boston Consulting Group (BCG)
and Strategic Advisor at Life Biosciences

Panelist bios

KEYNOTE

Keynote Dialogue 1: Innovation and Access

11:25 am – 12:10 pm

Panel Introduction    Register

Co-Chairs
Susan Desmond-Hellmann
CEO
Bill & Melinda Gates Foundation

Scott Gottlieb
Former Commissioner
U.S. FDA

PANEL 4

CEOs Panel : How will we be paying for medicine 10 years from now?

01:00 pm – 2:05  pm

Panel Introduction    Register

Co-Chairs
Susan Desmond-Hellmann
CEO
Bill & Melinda Gates Foundation

Mike Rosenblatt
Chief Medical Officer
Flagship Pioneering

Panelists
Albert Bourla
Chief Executive Officer
Pfizer Inc.

Jacqualyn Fouse,
Chief Executive Officer
Agios Pharmaceuticals

Christophe Weber,
CEO
Takeda Pharmaceuticals, Inc.

Panelist bios

PANEL 5

Marriage between Technology & Medicine

2:10 pm – 3:25 pm

Panel Introduction    Register

Chair
Bengt Samuelsson
Nobel Laureate; Former President, Karolinska Institute; Former Chairman
Nobel Foundation

Panelists
Steve Rosenberg
Senior VP & General Manager
Oracle Health (Lens: information/digital)

Eric Topol
Executive VP and Chair of Innovative Medicine Scripps Research; Director & Founder
Scripps Research Translational Institute; Author, Deep Learning

Panelist bios

KEYNOTE

Dialogue : Delivering on the patient promise of gene therapy

03:25 pm – 04:05 pm

Panel Introduction    Register

Chair
Kathy High
President and Head of R&D
Spark Therapeutics